Retinal Vein Occlusions: Therapeutic Switch in Macular Oedema Treatment with a 12-Month Follow-Up

Ophthalmic Research

Volumn 55, Issue 3, 2016, Pages 152-158

  Chiquet, Christophe ^a,b   Bron, Alain M ^a,c   Straub, Morgane ^a   Dupuy, Caroline ^a   Isaico, Rodica ^a   Aptel, Florent ^a,b   Creuzot Garcher, Catherine ^a,c  

^a University Hospital   (France)

^b UNIV GRENOBLE ALPES   (France)

^c CENTRE DES SCIENCES DU GOÛT ET DE L ALIMENTATION   (France)

Author keywords

Antivascular endothelial growth factor agent; Bevacizumab; Intravitreal dexamethasone implant; Retinal vein occlusion; Switch

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; ANGIOGENESIS INHIBITOR; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; BLEEDING; CENTRAL MACULAR THICKNESS; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; INTRAVITREAL HEMORRHAGE; MACULAR EDEMA; MALE; MULTICENTER STUDY; NEOVASCULAR GLAUCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; CLINICAL TRIAL; COMPLICATION; DRUG IMPLANT; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DEXAMETHASONE; DRUG IMPLANTS; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84954432448     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000442258     Document Type: Article

References (54)

1. Laouri M, Chen E, Looman M, Gallagher M: The burden of disease of retinal vein occlusion: review of the literature. Eye (Lond) 2011; 25: 981-988.
2. Coscas G, Loewenstein A, Augustin A, Bandello F, Battaglia Parodi M, Lanzetta P, Mones J, de Smet M, Soubrane G, Staurenghi G: Management of retinal vein occlusion-consensus document. Ophthalmologica 2011; 226: 4-28.
3. Rehak M, Wiedemann P: Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost 2010; 8: 1886-1894.
4. Hayreh SS: Retinal vein occlusion. Indian J Ophthalmol 1994; 42: 109-132.
5. Gutman FA, Zegarra H: Macular edema secondary to occlusion of the retinal veins. Surv Ophthalmol 1984; 28(suppl):462-470.
6. Hayreh SS: Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005; 24: 493-519.
7. Awdeh RM, Elsing SH, Deramo VA, Stinnett S, Lee PP, Fekrat S: Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item national eye institute visual function questionnaire. Br J Ophthalmol 2010; 94: 319-323.
8. Suner IJ, Bressler NM, Varma R, Lee P, Dolan CM, Ward J, Colman S, Rubio RG: Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmol 2013; 131: 851-856.
9. Pfister M, Rothweiler F, Michaelis M, Cinatl J Jr, Schubert R, Koch FH, Koss MJ: Correlation of inflammatory and proangiogenic cytokines from undiluted vitreous samples with spectral domain OCT scans, in untreated branch retinal vein occlusion. Clin Ophthalmol 2013; 7: 1061-1067.
10. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984; 98: 271-282.
11. Channa R, Smith M, Campochiaro PA: Treatment of macular edema due to retinal vein occlusions. Clin Ophthalmol 2011; 5: 705-713.
12. Campochiaro PA: Anti-vascular endothelial growth factor treatment for retinal vein occlusions. Ophthalmologica 2012; 227(suppl 1): 30-35.
13. Varma R, Bressler NM, Suner I, Lee P, Dolan CM, Ward J, Colman S, Rubio RG; BRAVO and CRUISE Study Groups: Improved visionrelated function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology 2012; 119: 2108-2118.
14. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG; BRAVO Investigators: Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1102-1112.
15. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-1146.
16. Ferrara N, Damico L, Shams N, Lowman H, Kim R: Development of ranibizumab, an antivascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26: 859-870.
17. Lu Y, Su L, Xu X: Bevacizumab for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis. J Ocul Pharmacol Ther 2013; 29: 702-708.
18. Ferrara DC, Koizumi H, Spaide RF: Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007; 144: 864-871.
19. Singer MA, Cohen SR, Groth SL, Porbandarwalla S: Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions. Clin Ophthalmol 2013; 7: 1377-1383.
20. Matsumoto Y, Freund KB, Peiretti E, Cooney MJ, Ferrara DC, Yannuzzi LA: Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 2007; 27: 426-431.
21. Yasuda S, Kondo M, Kachi S, Ito Y, Terui T, Ueno S, Terasaki H: Rebound of macular edema after intravitreal bevacizumab therapy in eyes with macular edema secondary to branch retinal vein occlusion. Retina 2011; 31: 1075-1082.
22. Alshareef RA, Garg SJ, Hsu J, Vander J, Park C, Spirn MJ: Intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion persisting despite multiple intravitreal bevacizumab injections. J Ocul Pharmacol Ther 2014; 30: 512-516.
23. Yoo SG, Kim JH, Lee TG, Kim CG, Kim JW: Short-term efficacy of intravitreal triamcinolone acetonide for macular edema secondary to retinal vein occlusion that is refractory to intravitreal bevacizumab. Indian J Ophthalmol 2015; 63: 25-29.
24. Lehmann-Clarke L, Dirani A, Mantel I, Ambresin A: The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion. Klin Monatsbl Augenheilkd 2015; 232: 552-555.
25. Sharareh B, Gallemore R, Taban M, Onishi S, Wallsh J: Recalcitrant macular edema after intravitreal bevacizumab is responsive to an intravitreal dexamethasone implant in retinal vein occlusion. Retina 2013; 33: 1227-1231.
26. Conrath J, Giorgi R, Raccah D, Ridings B: Foveal avascular zone in diabetic retinopathy: quantitative vs qualitative assessment. Eye (Lond) 2005; 19: 322-326.
27. Bhisitkul RB, Campochiaro PA, Shapiro H, Rubio RG: Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology 2013; 120: 1057-1063.
28. Holladay JT: Visual acuity measurements. J Cataract Refract Surg 2004; 30: 287-290.
29. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG: Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118: 2041-2049.
30. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY: Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118: 1594-1602.
31. Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA: Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 Copernicus Study. Am J Ophthalmol 2013; 155: 429-437 e427.
32. Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A: Benefit from bevacizumab for macular edema in central retinal vein occlusion: Twelve-month results of a prospective, randomized study. Ophthalmology 2012; 119: 2587-2591.
33. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P: Ranibizumab for macular edema due to retinal vein occlusions: longterm follow-up in the horizon trial. Ophthalmology 2012; 119: 802-809.
34. Varma R, Bressler NM, Suner I, Lee P, Dolan CM, Ward J, Colman S, Rubio RG: Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology 2011; 119: 2108-2118.
35. Narayanan R, Panchal B, Das T, Chhablani J, Jalali S, Ali MH: A randomised, doublemasked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL report No 1. Br J Ophthalmol 2015; 99: 954-959.
36. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A: Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN Study. Ophthalmology 2014; 121: 209-219.
37. Dirani A, Mantel I, Ambresin A: Recurrent macular edema in central retinal vein occlusion treated with intravitreal ranibizumab using a modified treat and extend regimen. Klin Monatsbl Augenheilkd 2015; 232: 538-541.
38. Kim M, Lee DH, Byeon SH, Koh HJ, Kim SS, Lee SC: Comparison of intravitreal bevacizumab and dexamethasone implant for the treatment of macula oedema associated with branch retinal vein occlusion. Br J Ophthalmol 2015; 99: 1271-1276.
39. Bezatis A, Spital G, Hohn F, Maier M, Clemens CR, Wachtlin J, Lehmann F, Hattenbach LO, Feltgen N, Meyer CH: Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up-the SOLO Study. Acta Ophthalmol 2013; 91:e340-e347.
40. Capone A Jr, Singer MA, Dodwell DG, Dreyer RF, Oh KT, Roth DB, Walt JG, Scott LC, Hollander DA: Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (SHASTA Study). Retina 2014; 34: 342-351.
41. Joshi L, Yaganti S, Gemenetzi M, Lightman S, Lindfield D, Liolios V, Menezo V, Shao E, Taylor SR: Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Br J Ophthalmol 2013; 97: 1040-1044.
42. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT: Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 2009; 29: 723-731.
43. Schaal S, Kaplan HJ, Tezel TH: Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in agerelated macular degeneration? Ophthalmology 2008; 115: 2199-2205.
44. Campochiaro PA, Hafiz G, Mir TA, Scott AW, Sophie R, Shah SM, Ying HS, Lu L, Chen C, Campbell JP, Kherani S, Zimmer-Galler I, Wenick A, Han I, Paulus Y, Sodhi A, Wang G, Qian J: Pro-permeability factors after dexamethasone implant in retinal vein occlusion: the Ozurdex for Retinal Vein Occlusion (ORVO) Study. Am J Ophthalmol 2015; 160: 313-321.
45. Karia N: Retinal vein occlusion: pathophysiology and treatment options. Clin Ophthalmol 2010; 4: 809-816.
46. Campochiaro PA, Choy DF, Do DV, Hafiz G, Shah SM, Nguyen QD, Rubio R, Arron JR: Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology 2009; 116: 2158-2164.
47. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC: Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 2008; 57: 1026-1033.
48. Goel N, Kumar V, Ghosh B: Ischemic maculopathy following intravitreal bevacizumab for refractory diabetic macular edema. Int Ophthalmol 2011; 31: 39-42.
49. Sabet-Peyman EJ, Heussen FM, Thorne JE, Casparis H, Patel SJ, Do DV: Progression of macular ischemia following intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging 2009; 40: 316-318.
50. Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG: Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology 2012; 120: 795-802.
51. Wong IY, Iu LP, Koizumi H, Lai WW: The inner segment/outer segment junction: what have we learnt so far? Curr Opin Ophthalmol 2012; 23: 210-218.
52. Domalpally A, Peng Q, Danis R, Blodi B, Scott IU, Ip M; SCORE Study Research Group: Association of outer retinal layer morphology with visual acuity in patients with retinal vein occlusion: SCORE Study Report 13. Eye (Lond) 2012; 26: 919-924.
53. Jonas JB, Rensch F: Decreased retinal vein diameter after intravitreal triamcinolone for retinal vein occlusions. Br J Ophthalmol 2007; 91: 1711-1712.
54. Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ: Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular agerelated macular degeneration. Ophthalmology 2009; 116: 1755-1761.